BP Update - RA, page-33

First 33 Last

Share
Profile

Follow
Barman76

3,999 Posts.

315

22/02/17

19:29

Post #: 22822850
Share

Originally posted by hottuna ↑

there's a seminal paper on perverse incentives in clinical trials by Dr Tony Fiorino that might be relevant

http://ascopubs.org/doi/full/10.1200/JCO.2007.11.1930

In stark contrast, the development-stage company is often crudely valued on the basis of its product candidates, both the number of molecules and their stage in clinical development. Phase III compounds are highly valued by the market because they are thought to have been “de-risked” (ie, phase III compounds are presumed to have successfully navigated earlier clinical trials that provided good evidence of safety and efficacy). This creates very strong incentive for development-stage companies to push products along into phase III
...
Given a set of questionable phase II data, the stock price of a company would suffer far more if management concluded it would be improper to expend shareholder capital on a phase III program likely to fail than if management decided to forge ahead into phase III on the basis of some dubious, post hoc subgroup analyses.
...
From among these groups of investors and money managers, companies are almost always able to raise capital and keep moving undeserving compounds forward in development. The terms may not always be to management's liking, but the capital is there waiting. Thus, the company remains afloat for a few more years, salaries are paid, stock options granted, and the phase III trial is funded, and if they get lucky, the phase III trial just might work and then there will be a lot more money for everyone involved.

Expand

Anyone can find something to back up any slanted view.

MSB Price at posting: $1.69 Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

IVZ

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

AZL

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

BIO

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

BOE

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

PAM

PAM secures high-grade Chilean copper play in strong territory

There are more pages in this discussion • 1 more message in this thread...

First 33 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.06		Change -0.065(5.78%)		Mkt cap ! $1.255B

Open	High	Low	Value	Volume
$1.14	$1.16	$1.06	$7.816M	7.117M

Buyers (Bids)

No.	Vol.	Price($)
9	97385	$1.06

Sellers (Offers)

Price($)	Vol.	No.
$1.07	39747	14

View Market Depth

No.	Vol.	Price($)
4	5776	1.070
18	161559	1.065
23	289780	1.060
14	137241	1.055
19	697836	1.050

Price($)	Vol.	No.
1.075	104229	17
1.080	130786	14
1.085	194016	13
1.090	53365	6
1.095	55724	4

Last trade - 15.41pm 29/07/2024 (20 minute delay)

MSB (ASX) Chart

BP Update - RA, page-33

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

PAM secures high-grade Chilean copper play in strong territory

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

BP Update - RA, page-33

Top Stories

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

PAM secures high-grade Chilean copper play in strong territory

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News